These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16027519)

  • 41. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
    Lupino E; Ramondetti C; Buccinnà B; Piccinini M
    Biochem Pharmacol; 2014 Nov; 92(2):235-50. PubMed ID: 25264277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
    Radujkovic A; Schad M; Topaly J; Veldwijk MR; Laufs S; Schultheis BS; Jauch A; Melo JV; Fruehauf S; Zeller WJ
    Leukemia; 2005 Jul; 19(7):1198-206. PubMed ID: 15902298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
    Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
    Stoehr M; Mozet C; Boehm A; Aigner A; Dietz A; Wichmann G
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):827-37. PubMed ID: 24562588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
    Miyoshi T; Nagai T; Ohmine K; Nakamura M; Kano Y; Muroi K; Komatsu N; Ozawa K
    Biochem Pharmacol; 2005 Jun; 69(11):1585-94. PubMed ID: 15896338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
    Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
    Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
    Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
    Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. STI-571: an anticancer protein-tyrosine kinase inhibitor.
    Roskoski R
    Biochem Biophys Res Commun; 2003 Oct; 309(4):709-17. PubMed ID: 13679030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
    Chrobák L; Voglová J
    Acta Medica (Hradec Kralove); 2003; 46(3):85-9. PubMed ID: 14677715
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
    Korycka A; Robak T
    Leuk Lymphoma; 2003 Sep; 44(9):1549-55. PubMed ID: 14565659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model.
    Merimsky O; Gorzalczany Y; Sagi-Eisenberg R
    Int J Oncol; 2007 Jul; 31(1):225-32. PubMed ID: 17549426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
    Ghosal N; Mais K; Shenjere P; Julyan P; Hastings D; Ward T; Ryder WD; Bruce I; Homer J; Slevin NJ
    Br J Oral Maxillofac Surg; 2011 Oct; 49(7):510-5. PubMed ID: 21071117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
    Chu TS; Chen JS; Lopez JP; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):979-84. PubMed ID: 18794444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
    J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
    Tzadok S; Beery E; Israeli M; Uziel O; Lahav M; Fenig E; Gil-Ad I; Weizman A; Nordenberg J
    Int J Oncol; 2010 Oct; 37(4):1043-51. PubMed ID: 20811727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.
    Wei Y; To KK; Au-Yeung SC
    J Pharmacol Sci; 2015 Dec; 129(4):210-5. PubMed ID: 26644081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
    Azam M; Latek RR; Daley GQ
    Cell; 2003 Mar; 112(6):831-43. PubMed ID: 12654249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.